The characteristics of the tumours suppressed by estrogen monotherapy in the WHI trial were ER+, HER2-, grade 1 or 2, and node negative [9] consistent with the Luminal A or less aggressive subtype of ER+ breast cancers. The gene discussed is ERBB2; the disease is breast carcinoma.